Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated April 1, 2024:
Effective May 1, 2024:
- Healthcare Administered Multiple Sclerosis
- Multiple Sclerosis
- Hereditary Angioedema (HAE)
- Opioids ER
- Risdiplam
- Spinraza
- Site of Care
- VMAT2 Inhibitors
- Xhance
- PAH (formerly Oral PAH)
- Skyclarys
- Xphozah
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.